chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 18.0
Sex: M
Vaccine: BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL, BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL
Symptoms: Aphonia, Chest X-ray abnormal, Chills, Computerised tomogram head, Demyelinating polyneuropathy
Clinical narrative: Initial report received from the Centers for Disease Control (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 336045). An 18-year-old male patient, with no reported medical history, received the following vaccinations on 22 September 2008: a left leg intramuscular dose of ADACEL (lot number C2998BA); an intramuscular dose of MENACTRA (lot number U2656AA); an intramuscular dose of BCG (lot number 52064); an intranasal dose of FLUMIST (Medimmune, lot number 500560P); MMR II (Merck, lot number 0356X); an intramuscular left leg dose of TWINRIX (GlaxoSmithKline, lot number AHAB128AB); and a subcutaneous dose of VARIVAX (lot number 0973). On 06 October 2008, 14 days post-vaccination, the patient complained of fever, chills, congestion, runny nose, sore throat, nausea, and and a productive cough. He was diagnosed with an upper respiratory infection at that time, and symptoms resolved in four days. On 15 October 2008, he presented to the emergency department with complaints of numbness and tingling in both hands and feet, and in his mouth, and weakness in the lower extremities while trying to climb stairs. At the time the impression was progressive idiopathic polyneuropathy. On 16 October 2008, he began developing progressive neurologic symptoms consistent with GUILLAIN-BARRE syndrome, including aphonia, dysphagia, and acute sensorimotor neurological deficits. He progressed to respiratory failure, and required mechanical ventilation and subsequent tracheostomy. CT and MRI of the head and echocardiogram were normal. A chest x-ray showed an infiltration. Electrodiagnostic studies revealed abnormal-non-recordable latency of bilateral phrenic nerves and highly suggestive of demyelinating and axonal polyneuropathy predominately involving motor nerves. Reticulocyte count was increased, and he developed hyperbilirubinemia. Diagnosis suggested hereditary hemolytic anemia vs. severe sepsis as cause of hemolysis. White blood count was 27.2. He was treated with intravenous immunoglobulins and plasmapheresis. During his hospitalization, he also developed orchitis, tachycardia, hypertension, and aspiration pneumonia. He remained hospitalized for 28 days, and was discharged on 13 November 2008. Outcome was unknown. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the network and determined to meet the proposed case definition of GUILLAIN-BARRE syndrome, with a level 2 of diagnostic certainty. Documents held by sender: None.
Age: 18.0
Sex: M
Vaccine: BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL, BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL
Symptoms: Dysphagia, Echocardiogram normal, Guillain-Barre syndrome, Haemolysis, Hyperbilirubinaemia
Clinical narrative: Initial report received from the Centers for Disease Control (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 336045). An 18-year-old male patient, with no reported medical history, received the following vaccinations on 22 September 2008: a left leg intramuscular dose of ADACEL (lot number C2998BA); an intramuscular dose of MENACTRA (lot number U2656AA); an intramuscular dose of BCG (lot number 52064); an intranasal dose of FLUMIST (Medimmune, lot number 500560P); MMR II (Merck, lot number 0356X); an intramuscular left leg dose of TWINRIX (GlaxoSmithKline, lot number AHAB128AB); and a subcutaneous dose of VARIVAX (lot number 0973). On 06 October 2008, 14 days post-vaccination, the patient complained of fever, chills, congestion, runny nose, sore throat, nausea, and and a productive cough. He was diagnosed with an upper respiratory infection at that time, and symptoms resolved in four days. On 15 October 2008, he presented to the emergency department with complaints of numbness and tingling in both hands and feet, and in his mouth, and weakness in the lower extremities while trying to climb stairs. At the time the impression was progressive idiopathic polyneuropathy. On 16 October 2008, he began developing progressive neurologic symptoms consistent with GUILLAIN-BARRE syndrome, including aphonia, dysphagia, and acute sensorimotor neurological deficits. He progressed to respiratory failure, and required mechanical ventilation and subsequent tracheostomy. CT and MRI of the head and echocardiogram were normal. A chest x-ray showed an infiltration. Electrodiagnostic studies revealed abnormal-non-recordable latency of bilateral phrenic nerves and highly suggestive of demyelinating and axonal polyneuropathy predominately involving motor nerves. Reticulocyte count was increased, and he developed hyperbilirubinemia. Diagnosis suggested hereditary hemolytic anemia vs. severe sepsis as cause of hemolysis. White blood count was 27.2. He was treated with intravenous immunoglobulins and plasmapheresis. During his hospitalization, he also developed orchitis, tachycardia, hypertension, and aspiration pneumonia. He remained hospitalized for 28 days, and was discharged on 13 November 2008. Outcome was unknown. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the network and determined to meet the proposed case definition of GUILLAIN-BARRE syndrome, with a level 2 of diagnostic certainty. Documents held by sender: None.
Age: 18.0
Sex: M
Vaccine: BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL, BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL
Symptoms: Hypertension, Hypoaesthesia, Hypoaesthesia oral, Immunoglobulin therapy, Lung infiltration
Clinical narrative: Initial report received from the Centers for Disease Control (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 336045). An 18-year-old male patient, with no reported medical history, received the following vaccinations on 22 September 2008: a left leg intramuscular dose of ADACEL (lot number C2998BA); an intramuscular dose of MENACTRA (lot number U2656AA); an intramuscular dose of BCG (lot number 52064); an intranasal dose of FLUMIST (Medimmune, lot number 500560P); MMR II (Merck, lot number 0356X); an intramuscular left leg dose of TWINRIX (GlaxoSmithKline, lot number AHAB128AB); and a subcutaneous dose of VARIVAX (lot number 0973). On 06 October 2008, 14 days post-vaccination, the patient complained of fever, chills, congestion, runny nose, sore throat, nausea, and and a productive cough. He was diagnosed with an upper respiratory infection at that time, and symptoms resolved in four days. On 15 October 2008, he presented to the emergency department with complaints of numbness and tingling in both hands and feet, and in his mouth, and weakness in the lower extremities while trying to climb stairs. At the time the impression was progressive idiopathic polyneuropathy. On 16 October 2008, he began developing progressive neurologic symptoms consistent with GUILLAIN-BARRE syndrome, including aphonia, dysphagia, and acute sensorimotor neurological deficits. He progressed to respiratory failure, and required mechanical ventilation and subsequent tracheostomy. CT and MRI of the head and echocardiogram were normal. A chest x-ray showed an infiltration. Electrodiagnostic studies revealed abnormal-non-recordable latency of bilateral phrenic nerves and highly suggestive of demyelinating and axonal polyneuropathy predominately involving motor nerves. Reticulocyte count was increased, and he developed hyperbilirubinemia. Diagnosis suggested hereditary hemolytic anemia vs. severe sepsis as cause of hemolysis. White blood count was 27.2. He was treated with intravenous immunoglobulins and plasmapheresis. During his hospitalization, he also developed orchitis, tachycardia, hypertension, and aspiration pneumonia. He remained hospitalized for 28 days, and was discharged on 13 November 2008. Outcome was unknown. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the network and determined to meet the proposed case definition of GUILLAIN-BARRE syndrome, with a level 2 of diagnostic certainty. Documents held by sender: None.
Age: 18.0
Sex: M
Vaccine: BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL, BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL
Symptoms: Mechanical ventilation, Muscular weakness, Nasal congestion, Nausea, Nerve conduction studies abnormal
Clinical narrative: Initial report received from the Centers for Disease Control (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 336045). An 18-year-old male patient, with no reported medical history, received the following vaccinations on 22 September 2008: a left leg intramuscular dose of ADACEL (lot number C2998BA); an intramuscular dose of MENACTRA (lot number U2656AA); an intramuscular dose of BCG (lot number 52064); an intranasal dose of FLUMIST (Medimmune, lot number 500560P); MMR II (Merck, lot number 0356X); an intramuscular left leg dose of TWINRIX (GlaxoSmithKline, lot number AHAB128AB); and a subcutaneous dose of VARIVAX (lot number 0973). On 06 October 2008, 14 days post-vaccination, the patient complained of fever, chills, congestion, runny nose, sore throat, nausea, and and a productive cough. He was diagnosed with an upper respiratory infection at that time, and symptoms resolved in four days. On 15 October 2008, he presented to the emergency department with complaints of numbness and tingling in both hands and feet, and in his mouth, and weakness in the lower extremities while trying to climb stairs. At the time the impression was progressive idiopathic polyneuropathy. On 16 October 2008, he began developing progressive neurologic symptoms consistent with GUILLAIN-BARRE syndrome, including aphonia, dysphagia, and acute sensorimotor neurological deficits. He progressed to respiratory failure, and required mechanical ventilation and subsequent tracheostomy. CT and MRI of the head and echocardiogram were normal. A chest x-ray showed an infiltration. Electrodiagnostic studies revealed abnormal-non-recordable latency of bilateral phrenic nerves and highly suggestive of demyelinating and axonal polyneuropathy predominately involving motor nerves. Reticulocyte count was increased, and he developed hyperbilirubinemia. Diagnosis suggested hereditary hemolytic anemia vs. severe sepsis as cause of hemolysis. White blood count was 27.2. He was treated with intravenous immunoglobulins and plasmapheresis. During his hospitalization, he also developed orchitis, tachycardia, hypertension, and aspiration pneumonia. He remained hospitalized for 28 days, and was discharged on 13 November 2008. Outcome was unknown. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the network and determined to meet the proposed case definition of GUILLAIN-BARRE syndrome, with a level 2 of diagnostic certainty. Documents held by sender: None.
Age: 18.0
Sex: M
Vaccine: BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL, BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL
Symptoms: Neurological symptom, Nuclear magnetic resonance imaging normal, Orchitis, Oropharyngeal pain, Paraesthesia
Clinical narrative: Initial report received from the Centers for Disease Control (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 336045). An 18-year-old male patient, with no reported medical history, received the following vaccinations on 22 September 2008: a left leg intramuscular dose of ADACEL (lot number C2998BA); an intramuscular dose of MENACTRA (lot number U2656AA); an intramuscular dose of BCG (lot number 52064); an intranasal dose of FLUMIST (Medimmune, lot number 500560P); MMR II (Merck, lot number 0356X); an intramuscular left leg dose of TWINRIX (GlaxoSmithKline, lot number AHAB128AB); and a subcutaneous dose of VARIVAX (lot number 0973). On 06 October 2008, 14 days post-vaccination, the patient complained of fever, chills, congestion, runny nose, sore throat, nausea, and and a productive cough. He was diagnosed with an upper respiratory infection at that time, and symptoms resolved in four days. On 15 October 2008, he presented to the emergency department with complaints of numbness and tingling in both hands and feet, and in his mouth, and weakness in the lower extremities while trying to climb stairs. At the time the impression was progressive idiopathic polyneuropathy. On 16 October 2008, he began developing progressive neurologic symptoms consistent with GUILLAIN-BARRE syndrome, including aphonia, dysphagia, and acute sensorimotor neurological deficits. He progressed to respiratory failure, and required mechanical ventilation and subsequent tracheostomy. CT and MRI of the head and echocardiogram were normal. A chest x-ray showed an infiltration. Electrodiagnostic studies revealed abnormal-non-recordable latency of bilateral phrenic nerves and highly suggestive of demyelinating and axonal polyneuropathy predominately involving motor nerves. Reticulocyte count was increased, and he developed hyperbilirubinemia. Diagnosis suggested hereditary hemolytic anemia vs. severe sepsis as cause of hemolysis. White blood count was 27.2. He was treated with intravenous immunoglobulins and plasmapheresis. During his hospitalization, he also developed orchitis, tachycardia, hypertension, and aspiration pneumonia. He remained hospitalized for 28 days, and was discharged on 13 November 2008. Outcome was unknown. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the network and determined to meet the proposed case definition of GUILLAIN-BARRE syndrome, with a level 2 of diagnostic certainty. Documents held by sender: None.
Age: 18.0
Sex: M
Vaccine: BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL, BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL
Symptoms: Paraesthesia oral, Peripheral sensory neuropathy, Plasmapheresis, Pneumonia aspiration, Polyneuropathy idiopathic progressive
Clinical narrative: Initial report received from the Centers for Disease Control (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 336045). An 18-year-old male patient, with no reported medical history, received the following vaccinations on 22 September 2008: a left leg intramuscular dose of ADACEL (lot number C2998BA); an intramuscular dose of MENACTRA (lot number U2656AA); an intramuscular dose of BCG (lot number 52064); an intranasal dose of FLUMIST (Medimmune, lot number 500560P); MMR II (Merck, lot number 0356X); an intramuscular left leg dose of TWINRIX (GlaxoSmithKline, lot number AHAB128AB); and a subcutaneous dose of VARIVAX (lot number 0973). On 06 October 2008, 14 days post-vaccination, the patient complained of fever, chills, congestion, runny nose, sore throat, nausea, and and a productive cough. He was diagnosed with an upper respiratory infection at that time, and symptoms resolved in four days. On 15 October 2008, he presented to the emergency department with complaints of numbness and tingling in both hands and feet, and in his mouth, and weakness in the lower extremities while trying to climb stairs. At the time the impression was progressive idiopathic polyneuropathy. On 16 October 2008, he began developing progressive neurologic symptoms consistent with GUILLAIN-BARRE syndrome, including aphonia, dysphagia, and acute sensorimotor neurological deficits. He progressed to respiratory failure, and required mechanical ventilation and subsequent tracheostomy. CT and MRI of the head and echocardiogram were normal. A chest x-ray showed an infiltration. Electrodiagnostic studies revealed abnormal-non-recordable latency of bilateral phrenic nerves and highly suggestive of demyelinating and axonal polyneuropathy predominately involving motor nerves. Reticulocyte count was increased, and he developed hyperbilirubinemia. Diagnosis suggested hereditary hemolytic anemia vs. severe sepsis as cause of hemolysis. White blood count was 27.2. He was treated with intravenous immunoglobulins and plasmapheresis. During his hospitalization, he also developed orchitis, tachycardia, hypertension, and aspiration pneumonia. He remained hospitalized for 28 days, and was discharged on 13 November 2008. Outcome was unknown. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the network and determined to meet the proposed case definition of GUILLAIN-BARRE syndrome, with a level 2 of diagnostic certainty. Documents held by sender: None.
Age: 18.0
Sex: M
Vaccine: BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL, BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL
Symptoms: Productive cough, Pyrexia, Respiratory failure, Respiratory tract congestion, Reticulocyte count increased
Clinical narrative: Initial report received from the Centers for Disease Control (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 336045). An 18-year-old male patient, with no reported medical history, received the following vaccinations on 22 September 2008: a left leg intramuscular dose of ADACEL (lot number C2998BA); an intramuscular dose of MENACTRA (lot number U2656AA); an intramuscular dose of BCG (lot number 52064); an intranasal dose of FLUMIST (Medimmune, lot number 500560P); MMR II (Merck, lot number 0356X); an intramuscular left leg dose of TWINRIX (GlaxoSmithKline, lot number AHAB128AB); and a subcutaneous dose of VARIVAX (lot number 0973). On 06 October 2008, 14 days post-vaccination, the patient complained of fever, chills, congestion, runny nose, sore throat, nausea, and and a productive cough. He was diagnosed with an upper respiratory infection at that time, and symptoms resolved in four days. On 15 October 2008, he presented to the emergency department with complaints of numbness and tingling in both hands and feet, and in his mouth, and weakness in the lower extremities while trying to climb stairs. At the time the impression was progressive idiopathic polyneuropathy. On 16 October 2008, he began developing progressive neurologic symptoms consistent with GUILLAIN-BARRE syndrome, including aphonia, dysphagia, and acute sensorimotor neurological deficits. He progressed to respiratory failure, and required mechanical ventilation and subsequent tracheostomy. CT and MRI of the head and echocardiogram were normal. A chest x-ray showed an infiltration. Electrodiagnostic studies revealed abnormal-non-recordable latency of bilateral phrenic nerves and highly suggestive of demyelinating and axonal polyneuropathy predominately involving motor nerves. Reticulocyte count was increased, and he developed hyperbilirubinemia. Diagnosis suggested hereditary hemolytic anemia vs. severe sepsis as cause of hemolysis. White blood count was 27.2. He was treated with intravenous immunoglobulins and plasmapheresis. During his hospitalization, he also developed orchitis, tachycardia, hypertension, and aspiration pneumonia. He remained hospitalized for 28 days, and was discharged on 13 November 2008. Outcome was unknown. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the network and determined to meet the proposed case definition of GUILLAIN-BARRE syndrome, with a level 2 of diagnostic certainty. Documents held by sender: None.
Age: 18.0
Sex: M
Vaccine: BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL, BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL
Symptoms: Rhinorrhoea, Sensorimotor disorder, Tachycardia, Tracheostomy, Upper respiratory tract infection
Clinical narrative: Initial report received from the Centers for Disease Control (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 336045). An 18-year-old male patient, with no reported medical history, received the following vaccinations on 22 September 2008: a left leg intramuscular dose of ADACEL (lot number C2998BA); an intramuscular dose of MENACTRA (lot number U2656AA); an intramuscular dose of BCG (lot number 52064); an intranasal dose of FLUMIST (Medimmune, lot number 500560P); MMR II (Merck, lot number 0356X); an intramuscular left leg dose of TWINRIX (GlaxoSmithKline, lot number AHAB128AB); and a subcutaneous dose of VARIVAX (lot number 0973). On 06 October 2008, 14 days post-vaccination, the patient complained of fever, chills, congestion, runny nose, sore throat, nausea, and and a productive cough. He was diagnosed with an upper respiratory infection at that time, and symptoms resolved in four days. On 15 October 2008, he presented to the emergency department with complaints of numbness and tingling in both hands and feet, and in his mouth, and weakness in the lower extremities while trying to climb stairs. At the time the impression was progressive idiopathic polyneuropathy. On 16 October 2008, he began developing progressive neurologic symptoms consistent with GUILLAIN-BARRE syndrome, including aphonia, dysphagia, and acute sensorimotor neurological deficits. He progressed to respiratory failure, and required mechanical ventilation and subsequent tracheostomy. CT and MRI of the head and echocardiogram were normal. A chest x-ray showed an infiltration. Electrodiagnostic studies revealed abnormal-non-recordable latency of bilateral phrenic nerves and highly suggestive of demyelinating and axonal polyneuropathy predominately involving motor nerves. Reticulocyte count was increased, and he developed hyperbilirubinemia. Diagnosis suggested hereditary hemolytic anemia vs. severe sepsis as cause of hemolysis. White blood count was 27.2. He was treated with intravenous immunoglobulins and plasmapheresis. During his hospitalization, he also developed orchitis, tachycardia, hypertension, and aspiration pneumonia. He remained hospitalized for 28 days, and was discharged on 13 November 2008. Outcome was unknown. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the network and determined to meet the proposed case definition of GUILLAIN-BARRE syndrome, with a level 2 of diagnostic certainty. Documents held by sender: None.
Age: 18.0
Sex: M
Vaccine: BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL, BCG, FLUN3, HEPAB, MMR, MNQ, TDAP, VARCEL
Symptoms: White blood cell count increased
Clinical narrative: Initial report received from the Centers for Disease Control (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 336045). An 18-year-old male patient, with no reported medical history, received the following vaccinations on 22 September 2008: a left leg intramuscular dose of ADACEL (lot number C2998BA); an intramuscular dose of MENACTRA (lot number U2656AA); an intramuscular dose of BCG (lot number 52064); an intranasal dose of FLUMIST (Medimmune, lot number 500560P); MMR II (Merck, lot number 0356X); an intramuscular left leg dose of TWINRIX (GlaxoSmithKline, lot number AHAB128AB); and a subcutaneous dose of VARIVAX (lot number 0973). On 06 October 2008, 14 days post-vaccination, the patient complained of fever, chills, congestion, runny nose, sore throat, nausea, and and a productive cough. He was diagnosed with an upper respiratory infection at that time, and symptoms resolved in four days. On 15 October 2008, he presented to the emergency department with complaints of numbness and tingling in both hands and feet, and in his mouth, and weakness in the lower extremities while trying to climb stairs. At the time the impression was progressive idiopathic polyneuropathy. On 16 October 2008, he began developing progressive neurologic symptoms consistent with GUILLAIN-BARRE syndrome, including aphonia, dysphagia, and acute sensorimotor neurological deficits. He progressed to respiratory failure, and required mechanical ventilation and subsequent tracheostomy. CT and MRI of the head and echocardiogram were normal. A chest x-ray showed an infiltration. Electrodiagnostic studies revealed abnormal-non-recordable latency of bilateral phrenic nerves and highly suggestive of demyelinating and axonal polyneuropathy predominately involving motor nerves. Reticulocyte count was increased, and he developed hyperbilirubinemia. Diagnosis suggested hereditary hemolytic anemia vs. severe sepsis as cause of hemolysis. White blood count was 27.2. He was treated with intravenous immunoglobulins and plasmapheresis. During his hospitalization, he also developed orchitis, tachycardia, hypertension, and aspiration pneumonia. He remained hospitalized for 28 days, and was discharged on 13 November 2008. Outcome was unknown. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the network and determined to meet the proposed case definition of GUILLAIN-BARRE syndrome, with a level 2 of diagnostic certainty. Documents held by sender: None.
Age: 20.0
Sex: M
Vaccine: MNQ
Symptoms: Areflexia, CSF protein normal, Dysstasia, Electromyogram abnormal, Gait disturbance
Clinical narrative: Initial reported received from the Centers for Disease Control and Prevention (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 339593). A 20 year old male patient with no recent illness or past medical history developed GUILLIAN BARRE syndrome one week post vaccination. On 19 August 2008 the patient received MENACTRA (lot number 49281/0589/05) intramuscularly in the right arm. On 28 August 2008 the patient developed GUILLIAN BARRE which required a seven day hospitalization, IV (intravenous) gammaglobulin, and acute rehab. Hospital medical records revealed that the patient had lower extremity weakness, difficulty walking and standing from sitting, diffuse paresthesias for four days. The patient was seen in the emergency room, found to be areflexic and transferred to a higher level of care. Diagnostics included the following: normal: CSF protein, MRI of the brain, C spine and L spine, abnormal: EMG and nerve conduction studies. He was treated with IVIG for four days. The patient was also noted to have received a blood transfusion. He improved and was discharged to an inpatient rehab. The patient was reported as recovered. The illness was reported as life threatening. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the health authority and determined to meet the proposed agency case definition of GUILLAIN-BARRE syndrome, with a level 3 of diagnostic certainty.
Age: 20.0
Sex: M
Vaccine: MNQ
Symptoms: Guillain-Barre syndrome, Immunoglobulin therapy, Muscular weakness, Nerve conduction studies abnormal, Nuclear magnetic resonance imaging brain normal
Clinical narrative: Initial reported received from the Centers for Disease Control and Prevention (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 339593). A 20 year old male patient with no recent illness or past medical history developed GUILLIAN BARRE syndrome one week post vaccination. On 19 August 2008 the patient received MENACTRA (lot number 49281/0589/05) intramuscularly in the right arm. On 28 August 2008 the patient developed GUILLIAN BARRE which required a seven day hospitalization, IV (intravenous) gammaglobulin, and acute rehab. Hospital medical records revealed that the patient had lower extremity weakness, difficulty walking and standing from sitting, diffuse paresthesias for four days. The patient was seen in the emergency room, found to be areflexic and transferred to a higher level of care. Diagnostics included the following: normal: CSF protein, MRI of the brain, C spine and L spine, abnormal: EMG and nerve conduction studies. He was treated with IVIG for four days. The patient was also noted to have received a blood transfusion. He improved and was discharged to an inpatient rehab. The patient was reported as recovered. The illness was reported as life threatening. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the health authority and determined to meet the proposed agency case definition of GUILLAIN-BARRE syndrome, with a level 3 of diagnostic certainty.
Age: 20.0
Sex: M
Vaccine: MNQ
Symptoms: Nuclear magnetic resonance imaging normal, Paraesthesia, Transfusion
Clinical narrative: Initial reported received from the Centers for Disease Control and Prevention (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 339593). A 20 year old male patient with no recent illness or past medical history developed GUILLIAN BARRE syndrome one week post vaccination. On 19 August 2008 the patient received MENACTRA (lot number 49281/0589/05) intramuscularly in the right arm. On 28 August 2008 the patient developed GUILLIAN BARRE which required a seven day hospitalization, IV (intravenous) gammaglobulin, and acute rehab. Hospital medical records revealed that the patient had lower extremity weakness, difficulty walking and standing from sitting, diffuse paresthesias for four days. The patient was seen in the emergency room, found to be areflexic and transferred to a higher level of care. Diagnostics included the following: normal: CSF protein, MRI of the brain, C spine and L spine, abnormal: EMG and nerve conduction studies. He was treated with IVIG for four days. The patient was also noted to have received a blood transfusion. He improved and was discharged to an inpatient rehab. The patient was reported as recovered. The illness was reported as life threatening. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the health authority and determined to meet the proposed agency case definition of GUILLAIN-BARRE syndrome, with a level 3 of diagnostic certainty.
Age: 17.0
Sex: F
Vaccine: MNQ
Symptoms: Fatigue, Headache, Neutrophil count increased, Pain in extremity, Pyrexia
Clinical narrative: This case was received from a health professional on 16 February 2009. A 17-year-old female patient, with a history of allergies to Bactrim, Keflex, and Amoxicillin, received an intramuscular left deltoid injection of MENACTRA (lot number U2668AA) on the morning of 16 February 2009. Later that evening, she reported a headache, fatigue, and left arm and leg pain. She was prescribed Tylenol, fluids, and rest. On 20 February 2009, she reported to emergency department with ongoing symptoms, and was diagnosed with a viral illness. A CBC showed increased neutraphils and a urinalysis was positive for bacteria. No cultures were taken, Treatment included rest, fluids, and ibuprofen. On 23 February 2009 the patient's parent reported that she was recovering. Follow up information received 23 March 2009 from a health care professional. According to the reporter, the patient had an oral temperature of 98.7 degrees Fahrenheit on 17 February 2009. The patient had not had any recent illness exposures prior to vaccination and the nature of the viral illness was not known. The patient fully recovered and returned to school on 24 February 2009.
Age: 17.0
Sex: F
Vaccine: MNQ
Symptoms: Urine analysis abnormal, Viral infection
Clinical narrative: This case was received from a health professional on 16 February 2009. A 17-year-old female patient, with a history of allergies to Bactrim, Keflex, and Amoxicillin, received an intramuscular left deltoid injection of MENACTRA (lot number U2668AA) on the morning of 16 February 2009. Later that evening, she reported a headache, fatigue, and left arm and leg pain. She was prescribed Tylenol, fluids, and rest. On 20 February 2009, she reported to emergency department with ongoing symptoms, and was diagnosed with a viral illness. A CBC showed increased neutraphils and a urinalysis was positive for bacteria. No cultures were taken, Treatment included rest, fluids, and ibuprofen. On 23 February 2009 the patient's parent reported that she was recovering. Follow up information received 23 March 2009 from a health care professional. According to the reporter, the patient had an oral temperature of 98.7 degrees Fahrenheit on 17 February 2009. The patient had not had any recent illness exposures prior to vaccination and the nature of the viral illness was not known. The patient fully recovered and returned to school on 24 February 2009.
Age: 18.0
Sex: M
Vaccine: HEPAB, MMR, MNQ, PPV
Symptoms: Areflexia, Asthenia, CSF culture, CSF lymphocyte count abnormal, CSF neutrophil count increased
Clinical narrative: Initial report received from the Centers for Disease Control and Prevention (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 339758). An 18-year-old male patient, who had no concurrent illnesses, or pre-existing medical history, had received a dose of MENACTRA (lot number U2572AA); a subcutaneous injection of MMR II, manufacturer Merck (lot number 0916X); and a dose of PNEUMOVAX, manufacturer Merck (lot number AHABB128AB) on 03 September 2008. The patient had received multiple vaccines in basic training. The patient presented on 20 September 2008 with complaint of a 10 day history of numbness of the toes initially thought to be due to his boots and was dismissed. At an unspecified amount of time later, the patient returned for evaluation with continued numbness that now was in both legs. He also complained of a productive cough and it was noted he had recent close contact with person/or persons with pneumonia. The patient was diagnosed at that time with Community Acquired Pneumonia and was started on antibiotics (traded name not provided). Several days later the patient developed tingling in his fingertips and legs with painful cramping in the calves. The patient was unable to walk up stairs and was having difficulty due to arm weakness. He was referred to the hospital for evaluation on 24 September 2008 and was hospitalized for seven days. During hospitalization, physical examination revealed abnormal sensation, reduced motor strength, abnormal gait and stance, and diminished or absent DTRs. The patient was diagnosed with GBS (GUILLAIN BARRE syndrome) following EMG/NCS testing. He was treated with IVIG with some improvement and was subsequently able to walk with a walker. Relevant diagnostic test and laboratory data revealed elevated protein in spinal fluid, and positive EMG/NCV. A chest x-ray was positive for right lung apex consolidation. EMG/NCS was positive for generalized sensorimotor polyradiculopathy with mixed axonal and acquired demyelinating features. CSF (cerebral spinal fluid) showed protein 179 and culture and gram stain revealed WBC 18.7, 7% lymphs, and 85.9% neutrophils. Urine protein SSA was high at 5. As of December 2008, the patient had fatigue and continued numbness, pain and spasm in his arms and legs. The service member was discharged permanently from the military. At the time of this report, the patient's recovery status was unknown. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the network and determined to meet the proposed case definition of GUILLAIN-BARRE Syndrome, with a level 1 of diagnostic certainty. Documents held by sender: None.
Age: 18.0
Sex: M
Vaccine: HEPAB, MMR, MNQ, PPV
Symptoms: CSF protein increased, CSF white blood cell count increased, Chest X-ray abnormal, Demyelination, Electromyogram abnormal
Clinical narrative: Initial report received from the Centers for Disease Control and Prevention (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 339758). An 18-year-old male patient, who had no concurrent illnesses, or pre-existing medical history, had received a dose of MENACTRA (lot number U2572AA); a subcutaneous injection of MMR II, manufacturer Merck (lot number 0916X); and a dose of PNEUMOVAX, manufacturer Merck (lot number AHABB128AB) on 03 September 2008. The patient had received multiple vaccines in basic training. The patient presented on 20 September 2008 with complaint of a 10 day history of numbness of the toes initially thought to be due to his boots and was dismissed. At an unspecified amount of time later, the patient returned for evaluation with continued numbness that now was in both legs. He also complained of a productive cough and it was noted he had recent close contact with person/or persons with pneumonia. The patient was diagnosed at that time with Community Acquired Pneumonia and was started on antibiotics (traded name not provided). Several days later the patient developed tingling in his fingertips and legs with painful cramping in the calves. The patient was unable to walk up stairs and was having difficulty due to arm weakness. He was referred to the hospital for evaluation on 24 September 2008 and was hospitalized for seven days. During hospitalization, physical examination revealed abnormal sensation, reduced motor strength, abnormal gait and stance, and diminished or absent DTRs. The patient was diagnosed with GBS (GUILLAIN BARRE syndrome) following EMG/NCS testing. He was treated with IVIG with some improvement and was subsequently able to walk with a walker. Relevant diagnostic test and laboratory data revealed elevated protein in spinal fluid, and positive EMG/NCV. A chest x-ray was positive for right lung apex consolidation. EMG/NCS was positive for generalized sensorimotor polyradiculopathy with mixed axonal and acquired demyelinating features. CSF (cerebral spinal fluid) showed protein 179 and culture and gram stain revealed WBC 18.7, 7% lymphs, and 85.9% neutrophils. Urine protein SSA was high at 5. As of December 2008, the patient had fatigue and continued numbness, pain and spasm in his arms and legs. The service member was discharged permanently from the military. At the time of this report, the patient's recovery status was unknown. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the network and determined to meet the proposed case definition of GUILLAIN-BARRE Syndrome, with a level 1 of diagnostic certainty. Documents held by sender: None.
Age: 18.0
Sex: M
Vaccine: HEPAB, MMR, MNQ, PPV
Symptoms: Exposure to communicable disease, Fatigue, Gait disturbance, Gram stain, Guillain-Barre syndrome
Clinical narrative: Initial report received from the Centers for Disease Control and Prevention (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 339758). An 18-year-old male patient, who had no concurrent illnesses, or pre-existing medical history, had received a dose of MENACTRA (lot number U2572AA); a subcutaneous injection of MMR II, manufacturer Merck (lot number 0916X); and a dose of PNEUMOVAX, manufacturer Merck (lot number AHABB128AB) on 03 September 2008. The patient had received multiple vaccines in basic training. The patient presented on 20 September 2008 with complaint of a 10 day history of numbness of the toes initially thought to be due to his boots and was dismissed. At an unspecified amount of time later, the patient returned for evaluation with continued numbness that now was in both legs. He also complained of a productive cough and it was noted he had recent close contact with person/or persons with pneumonia. The patient was diagnosed at that time with Community Acquired Pneumonia and was started on antibiotics (traded name not provided). Several days later the patient developed tingling in his fingertips and legs with painful cramping in the calves. The patient was unable to walk up stairs and was having difficulty due to arm weakness. He was referred to the hospital for evaluation on 24 September 2008 and was hospitalized for seven days. During hospitalization, physical examination revealed abnormal sensation, reduced motor strength, abnormal gait and stance, and diminished or absent DTRs. The patient was diagnosed with GBS (GUILLAIN BARRE syndrome) following EMG/NCS testing. He was treated with IVIG with some improvement and was subsequently able to walk with a walker. Relevant diagnostic test and laboratory data revealed elevated protein in spinal fluid, and positive EMG/NCV. A chest x-ray was positive for right lung apex consolidation. EMG/NCS was positive for generalized sensorimotor polyradiculopathy with mixed axonal and acquired demyelinating features. CSF (cerebral spinal fluid) showed protein 179 and culture and gram stain revealed WBC 18.7, 7% lymphs, and 85.9% neutrophils. Urine protein SSA was high at 5. As of December 2008, the patient had fatigue and continued numbness, pain and spasm in his arms and legs. The service member was discharged permanently from the military. At the time of this report, the patient's recovery status was unknown. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the network and determined to meet the proposed case definition of GUILLAIN-BARRE Syndrome, with a level 1 of diagnostic certainty. Documents held by sender: None.
Age: 18.0
Sex: M
Vaccine: HEPAB, MMR, MNQ, PPV
Symptoms: Hypoaesthesia, Hyporeflexia, Immunoglobulin therapy, Lung consolidation, Motor dysfunction
Clinical narrative: Initial report received from the Centers for Disease Control and Prevention (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 339758). An 18-year-old male patient, who had no concurrent illnesses, or pre-existing medical history, had received a dose of MENACTRA (lot number U2572AA); a subcutaneous injection of MMR II, manufacturer Merck (lot number 0916X); and a dose of PNEUMOVAX, manufacturer Merck (lot number AHABB128AB) on 03 September 2008. The patient had received multiple vaccines in basic training. The patient presented on 20 September 2008 with complaint of a 10 day history of numbness of the toes initially thought to be due to his boots and was dismissed. At an unspecified amount of time later, the patient returned for evaluation with continued numbness that now was in both legs. He also complained of a productive cough and it was noted he had recent close contact with person/or persons with pneumonia. The patient was diagnosed at that time with Community Acquired Pneumonia and was started on antibiotics (traded name not provided). Several days later the patient developed tingling in his fingertips and legs with painful cramping in the calves. The patient was unable to walk up stairs and was having difficulty due to arm weakness. He was referred to the hospital for evaluation on 24 September 2008 and was hospitalized for seven days. During hospitalization, physical examination revealed abnormal sensation, reduced motor strength, abnormal gait and stance, and diminished or absent DTRs. The patient was diagnosed with GBS (GUILLAIN BARRE syndrome) following EMG/NCS testing. He was treated with IVIG with some improvement and was subsequently able to walk with a walker. Relevant diagnostic test and laboratory data revealed elevated protein in spinal fluid, and positive EMG/NCV. A chest x-ray was positive for right lung apex consolidation. EMG/NCS was positive for generalized sensorimotor polyradiculopathy with mixed axonal and acquired demyelinating features. CSF (cerebral spinal fluid) showed protein 179 and culture and gram stain revealed WBC 18.7, 7% lymphs, and 85.9% neutrophils. Urine protein SSA was high at 5. As of December 2008, the patient had fatigue and continued numbness, pain and spasm in his arms and legs. The service member was discharged permanently from the military. At the time of this report, the patient's recovery status was unknown. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the network and determined to meet the proposed case definition of GUILLAIN-BARRE Syndrome, with a level 1 of diagnostic certainty. Documents held by sender: None.
Age: 18.0
Sex: M
Vaccine: HEPAB, MMR, MNQ, PPV
Symptoms: Muscle spasms, Muscular weakness, Nerve conduction studies abnormal, Pain in extremity, Paraesthesia
Clinical narrative: Initial report received from the Centers for Disease Control and Prevention (CDC) on 08 September 2009 and follow-up information on 16 September 2009 (VAERS number 339758). An 18-year-old male patient, who had no concurrent illnesses, or pre-existing medical history, had received a dose of MENACTRA (lot number U2572AA); a subcutaneous injection of MMR II, manufacturer Merck (lot number 0916X); and a dose of PNEUMOVAX, manufacturer Merck (lot number AHABB128AB) on 03 September 2008. The patient had received multiple vaccines in basic training. The patient presented on 20 September 2008 with complaint of a 10 day history of numbness of the toes initially thought to be due to his boots and was dismissed. At an unspecified amount of time later, the patient returned for evaluation with continued numbness that now was in both legs. He also complained of a productive cough and it was noted he had recent close contact with person/or persons with pneumonia. The patient was diagnosed at that time with Community Acquired Pneumonia and was started on antibiotics (traded name not provided). Several days later the patient developed tingling in his fingertips and legs with painful cramping in the calves. The patient was unable to walk up stairs and was having difficulty due to arm weakness. He was referred to the hospital for evaluation on 24 September 2008 and was hospitalized for seven days. During hospitalization, physical examination revealed abnormal sensation, reduced motor strength, abnormal gait and stance, and diminished or absent DTRs. The patient was diagnosed with GBS (GUILLAIN BARRE syndrome) following EMG/NCS testing. He was treated with IVIG with some improvement and was subsequently able to walk with a walker. Relevant diagnostic test and laboratory data revealed elevated protein in spinal fluid, and positive EMG/NCV. A chest x-ray was positive for right lung apex consolidation. EMG/NCS was positive for generalized sensorimotor polyradiculopathy with mixed axonal and acquired demyelinating features. CSF (cerebral spinal fluid) showed protein 179 and culture and gram stain revealed WBC 18.7, 7% lymphs, and 85.9% neutrophils. Urine protein SSA was high at 5. As of December 2008, the patient had fatigue and continued numbness, pain and spasm in his arms and legs. The service member was discharged permanently from the military. At the time of this report, the patient's recovery status was unknown. From the additional information received on 16 September 2009 from the CDC, this case was evaluated by the network and determined to meet the proposed case definition of GUILLAIN-BARRE Syndrome, with a level 1 of diagnostic certainty. Documents held by sender: None.